Envoyer à un ami

Samsung Bioepis' SB4 (BRENZYS™) Becomes First Etanercept Biosimilar to ...

- 12 Septembre 2016 modifié le 1 Janvier 1970

(BUSINESS WIRE)-- Samsung Bioepis Co., Ltd. today announced that BRENZYS a biosimilar referencing Enbrel® (etanercept), also known as SB4 – received regulatory approval in Canada for the treatment of rheumatoid arthritis and ankylosing spondylitis. BRENZYS will be commercialized in Canada by Merck Canada Inc.

“As evidenced in other markets, we believe BRENZYS will help drive down healthcare costs and increase patient access to one of the most widely used autoimmune treatment options in Canada,” said Christopher Hansung Ko, President & CEO of Samsung Bioepis. “We remain committed to advancing one of the industry's largest biosimilar pipelines, so that more patients across Canada can access affordable, high-quality treatment. ...

Source :